Delveinsight

AUGUST 2, 2020

The company has also signed a licensing agreement with Ono Pharmaceutical , a Japanese pharma company, transferring exclusive rights to develop and commercialise anamorelin in Japan, South Korea, and Taiwan. Cancer Cachexia Pipeline.

Marketing 94

Marketing Pharma Companies Development Hormones 94

pharmaphorum

SEPTEMBER 29, 2020

For example, under a traditional pharma/biotech collaboration and licensing model, a biotech partner may have primary responsibility for significant elements of research and early product development, and the pharma partner may lead the majority of later stage development, as well as post-approval commercial manufacture and supply.

Research 132

Research Gene Editing Development Gene 132

pharmaphorum

JULY 5, 2021

Parexel’s chief executive Jamie Macdonald said that in the past 18 months, the company “has continued its strong growth trajectory” in a market for outsourced clinical services that at conservative estimates is expected to grow at a rate of 8% to 9% in the coming years.

Clinical Trials 64

Clinical Trials Clinical Trials Trials Regulation 64

pharmaphorum

NOVEMBER 12, 2020

The mid-sized pharma group has also signed a collaboration with Florida, US-based Lacerta Therapeutics , adding more AAV capsids – well established as a staple for delivering gene therapy sequences – as well as another gene therapy candidate.

Gene Therapy 52

Gene Therapy Gene Manufacturing Contract Manufacturing 52

pharmaphorum

NOVEMBER 15, 2022

The panel began by addressing the difficulties companies can encounter in creating new out-licensing agreements and spinning out assets to form new companies. But he noted getting the right people on the right path to success allows companies to create a more impactful story to put to investors.

Life Science 96

Life Science Pharma Companies Marketing Production 96

pharmaphorum

JUNE 16, 2021

California biotech Ambrx Biopharma is hoping to raise $126 million from a listing on the New York Stock Exchange (NYSE) that will be used in part to fund clinical development of ARX-788, its HER2-targeting antibody drug conjugate (ADC). billion upfront, when it licensed the ADC from Daiichi Sankyo in 2019.

Antibody 57

Antibody Sales Drugs Trials 57

pharmaphorum

SEPTEMBER 8, 2022

Big pharma has already noted its interest in the area, as seen in Novartis’ investments. Last year, the company signed two deals in quick succession, which saw it form a licensing deal worth $1.3 billion with Artios Pharma and with iTheranostics for a number of diagnostic radiopharmaceuticals.

Manufacturing 105

Manufacturing Development Antibody Drugs 105

XTalks

SEPTEMBER 5, 2023

Xtalks spoke with Maria Reyes Boceta-Muñoz, Clinical Operations Head of Development R&D at GlaxoSmithKline in Spain, Portugal & Israel, to understand the current vaccine development climate and where the sector is headed. It is affected by factors such as complacency, convenience, confidence and cultural factors.

Vaccination 96

Vaccination Vaccine Development Clinical Trials 96

pharmaphorum

MAY 14, 2021

Merck KGaA had been developing the drug with partner Avillion and van Amstel’s team got in touch as soon as they heard the German pharma was considering selling it as part of a pipeline rethink. Licensed in from Ablynx in 2013 five years before a merger with Sanofi, German Merck recognised its potential.

Drugs 64

Drugs Licensing Licensing Development 64

pharmaphorum

NOVEMBER 23, 2021

GSK gets worldwide rights to the potentially first-in-class drug, with the exception of China, and will be wholly responsible in its markets for clinical development and commercialisation. Arrowhead said the partnering process for ARO-HSD was competitive and GSK was one of several suitors for the drug.

Sales 52

Sales Drugs Trials RNA 52

pharmaphorum

MAY 21, 2021

It builds on the company’s four partnership projects: two with the generics and biosimilars firm Hikma, one with US biotech Inhibrix and another with an unnamed biosimilars partner. An AIM listing will help the company become established and bring it to the attention of investors and the wider public, said Howell. “We

Insulin 52

Insulin Drugs Production Marketing 52

pharmaphorum

DECEMBER 21, 2021

Novartis has joined the ranks of big pharma companies developing TIGIT-targeted drugs for cancer, and found its candidate in an existing partner, Chinese biotech BeiGene. Pharma companies are looking at whether blocking TIGIT as well as PD-1/PD-L1 can improve the efficacy of cancer immunotherapy.

Drugs 98

Drugs Antibody Pharma Companies Development 98

The Pharma Data

NOVEMBER 5, 2020

The demand for an effective drug for nail fungus is high and MOB-015 can achieve a unique market position through its high antifungal effect,” says Anna Ljung, CEO of Moberg Pharma.

Marketing 40

Marketing Production Regulation Containment 40

Pharmaceutical Technology

MAY 26, 2023

The British company’s expanded facilities boasts of 11 suites, including two class B filling suites with class A filling cabinets, warehousing and quality control laboratory capability. One big pharma company has already given the seal of approval with a successful customer quality audit.

DNA 130

DNA Manufacturing Gene Gene Therapy 130

The Pharma Data

DECEMBER 16, 2020

More Vaccine Development : In France, specialty vaccine company Valneva SE announced it was launching a Phase I/II study for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. and will leverage a major COVID-19 vaccine partnership the company struck with the U.K. The study will be conducted in the U.K.

Vaccination 52

Vaccination Vaccine DNA Antibody 52